DexCom Inc (DXCM) is a leading medical devices business with stocks listed in the US. It opened the day at US$138.91 after a previous close of US$137.87. During the day the price has varied from a low of USD134.39 to a high of USD139.24. The latest price was USD138.01 (25 minute delay). DexCom is listed on the NASDAQ. All prices are listed in US Dollars.
Our top pick for
US stocks
Our top pick for
Best for beginner
Our top pick for
Dividend investing
DexCom's shares were split on a 4:1 basis on 12 June 2022. So if you had owned 1 share the day before the split, the next day you would own 4 shares. This wouldn't directly have changed the overall worth of your DexCom shares – just the quantity. However, indirectly, the new 75% lower share price could have impacted the market appetite for DexCom shares which in turn could have impacted DexCom's share price.
| Open | US$138.91 |
|---|---|
| High | US$139.24 |
| Low | US$134.39 |
| Close | US$138.01 |
| Previous close | US$137.87 |
| Change | US$0.14 |
| Change % | 0.1015% |
| Volume | 4,062,169 |
| 52-week range | US$74.75 - US$142 |
|---|---|
| 50-day moving average | US$129.1176 |
| 200-day moving average | US$114.9612 |
| Target price | US$151.32 |
| PE ratio | 103.3077 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | US$1.3 |
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Historical closes compared with the last close of $138.01
| 1 week (2024-04-19) | 5.58% |
|---|---|
| 1 month (2024-03-26) | -1.37% |
| 3 months (2024-01-26) | 13.16% |
| 6 months (2023-10-26) | 70.19% |
| 1 year (2023-04-25) | 11.33% |
|---|---|
| 2 years (2022-04-25) | 24.76% |
| 3 years (2021-04-26) | 31.82% |
| 5 years (2019-04-26) | 344.58% |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Valuing DexCom stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of DexCom's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
DexCom's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 103x. In other words, DexCom shares trade at around 103x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
DexCom's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.5317. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into DexCom's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
DexCom's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$783.7 million (£0.0 million).
The EBITDA is a measure of a DexCom's overall financial performance and is widely used to measure stock profitability.
Over the last 12 months, DexCom's shares have ranged in value from as little as US$74.75 up to US$142. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while DexCom's is 1.207. This would suggest that DexCom's shares are a little bit more volatile than the average for this exchange and represent, relatively speaking, a slightly higher risk (but potentially also market-beating returns).
| Revenue TTM | US$3.6 billion |
|---|---|
| Operating margin TTM | 20.97% |
| Gross profit TTM | US$1.9 billion |
| Return on assets TTM | 6.41% |
| Return on equity TTM | 25.78% |
| Profit margin | 14.95% |
| Book value | 5.367 |
| Market capitalisation | US$51.8 billion |
TTM: trailing 12 months
We're not expecting DexCom to pay a dividend over the next 12 months.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like DexCom.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 29.18
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and DexCom's overall score of 29.18 (as at 12/31/2018) is nothing to write home about – landing it in it in the 50th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like DexCom is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 10.43/100
DexCom's environmental score of 10.43 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that DexCom is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 17.04/100
DexCom's social score of 17.04 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that DexCom is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 13.2/100
DexCom's governance score puts it squarely in the 6th percentile of companies rated in the same sector. That could suggest that DexCom is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. DexCom scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that DexCom has, for the most part, managed to keep its nose clean.
DexCom Inc was last rated for ESG on: 2019-01-01.
| Total ESG score | 29.18 |
|---|---|
| Total ESG percentile | 50.12 |
| Environmental score | 10.43 |
| Environmental score percentile | 6 |
| Social score | 17.04 |
| Social score percentile | 6 |
| Governance score | 13.2 |
| Governance score percentile | 6 |
| Level of controversy | 2 |
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Everything we know about the Sun Silver IPO, plus information on how to buy in.
Everything we know about the Tasmea Limited IPO, plus information on how to buy in.
Steps to owning and managing Far Northern Resources shares.
Commodity ETFs can be used to hedge against inflation. Here's what they do, why they should be on your watchlist and how they can help your portfolio.
Looking for the best performing stocks in Australia? We update this list weekly.
Steps to owning and managing Gol Linhas Aéreas Inteligentes SA shares from Australia.
Trade ASX stocks and ETFs with a $2 brokerage fee and a low minimum investment of just $10.
These ETFs have the lowest fees on the market, but does that make them the best?
You've heard of CommSec but how does it stack up to the likes of IG, CMC Invest and other players in the market?
Westpac Share Trading allows you to take control of your investments. Find out if its right for you.
